Article info

Download PDFPDF

Response to: ‘Correspondence on ‘Safety and tolerability of nintedanib in patients with systemic sclerosis-associated interstitial lung disease: data from the SENSCIS trial’’ by Bredemeier
Free

Authors

  1. Correspondence to Professor James R Seibold, Scleroderma Research Consultants LLC, Aiken, South Carolina, USA; jamesrseibold{at}gmail.com
View Full Text

Citation

Seibold JR, Kohlbrenner V, Alves M, et al
Response to: ‘Correspondence on ‘Safety and tolerability of nintedanib in patients with systemic sclerosis-associated interstitial lung disease: data from the SENSCIS trial’’ by Bredemeier

Publication history

  • Received September 9, 2020
  • Accepted September 10, 2020
  • First published October 6, 2020.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.